UCB acquires Candid Therapeutics for $2.2 billion
Belgian pharmaceutical company UCB is acquiring U.S. autoimmune biotech Candid Therapeutics for $2.2 billion, with $2 billion paid upfront. The deal targets Candid's pipeline of T-cell engagers designed to treat autoimmune diseases. This acquisition underscores UCB's strategic focus on expanding its immunology portfolio.
Key facts
- UCB is acquiring Candid Therapeutics for $2.2 billion.
- $2 billion is paid upfront for Candid's pipeline.
- Candid develops T-cell engagers targeting autoimmune diseases.
- UCB is a Belgian pharmaceutical company.
- Candid Therapeutics is a U.S. biotech firm.
- The acquisition focuses on autoimmune disease treatments.
Entities
Institutions
- UCB
- Candid Therapeutics
Locations
- Belgium
- United States
Sources
- Quartz —